Výsledky vyhledávání - "T. Rossmanith"

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)

Autor: Andrea Rubbert-Roth, Hans-Peter Tony, Harald Burkhardt, Martin Aringer, Klaus Krueger, Ulf Müller-Ladner, T. Rossmanith, Michaela Koehm, Marina Backhaus, Rieke Alten, Eva Herrmann, Annette Lehn, Eugen Feist, Frank Behrens, Siegfried Wassenberg, Herbert Kellner, Gerd R Burmester

Publikováno v: Rheumatology (Oxford, England)

Objective To investigate the efficacy and safety of rituximab + LEF in patients with RA. Methods In this investigator-initiated, randomized, double-blind, placebo-controlled phase 3 trial, patients with an inadequate response to LEF who had failed on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb210b4686b2ac48c90aa765fd72941e
http://europepmc.org/articles/PMC8566251

Zobrazit plný text záznamu

A data science approach to the selection of most informative readouts of the human intradermal capsaicin pain model to assess pregabalin effects

Autor: Miriam Wolters, Martin Zunftmeister, T. Rossmanith, Gerd Geisslinger, Carmen Walter, Bruno G. Oertel, Jörn Lötsch, Nerea Ferreirós, Sebastian Zinn

Publikováno v: Basic & Clinical Pharmacology & Toxicology. 126:318-331

Persistent and, in particular, neuropathic pain is a major healthcare problem with still insufficient pharmacological treatment options. This triggered research activities aimed at finding analgesics with a novel mechanism of action. Results of these

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01809f01ab6f3543e8b38543b00a03ac
https://doi.org/10.1111/bcpt.13337

Zobrazit plný text záznamu

POS1059 EFFICACY OF UST IN ACTIVE PsA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL

Autor: M. Köhm, T. Rossmanith, A. C. Foldenauer, H. Kellner, U. Kiltz, J. Rech, G. R. Burmester, D. M. Kofler, J. Brandt-Juergens, C. Jonetzko, H. Burkhardt, F. Behrens

Publikováno v: Annals of the Rheumatic Diseases. 81:850.2-851

BackgroundThe use of bDMARDs treatments in patients with psoriatic arthritis (PsA) usually requires treatment failure or intolerance of csDMARD/MTX before initiation. The value of MTX in combination with bDMARDs is still unclear. We designed an inves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc036f6c46cb819b5bc896401115261d
https://doi.org/10.1136/annrheumdis-2022-eular.3929

Zobrazit plný text záznamu

POS1094 CORRELATION OF FLUORESCENCE-OPTICAL IMAGING AND PHYSICIAN TJC/SJC ASSESSMENT AND ULTRASOUND IN PSORIASIS PATIENTS WITHOUT ARTHRITIS BUT MUSCULOSKELETAL COMPLAINTS WITHIN THE LAST 6 MONTHS

Autor: M. Köhm, S. Ohrndorf, X. Baraliakos, K. Hallmann, S. Kempinski, A. C. Foldenauer, T. Rossmanith, U. Henkemeier, F. Behrens

Publikováno v: Annals of the Rheumatic Diseases. 81:874.1-874

BackgroundPsoriasis (PsO) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to PsO; up to 40% of PsO patients develop PsA. The transition from PsO to PsA includes different stages

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b82fe88fa054367ae726e968ee3c62ce
https://doi.org/10.1136/annrheumdis-2022-eular.3987

Zobrazit plný text záznamu

Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001

Autor: T. Rossmanith, Mukul Ashtikar, Matthias G. Wacker, Gerd Geisslinger, Lisa Nothnagel, Michael J. Parnham, Fabian Jung, Manuela Thurn

Publikováno v: European Journal of Pharmaceutics and Biopharmaceutics. 134:144-152

Since many drugs in the therapy scheme of multiple sclerosis (MS) are applied parenterally with significant side effects, oral treatment is the most accepted therapy option for chronic diseases like MS. The drug candidate TMP-001, which has disease-m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2b987ac27bafbedd809cb00b3afaf42
https://doi.org/10.1016/j.ejpb.2018.11.012

Zobrazit plný text záznamu

AB0880 The objective automated measurement of fluorescence-signal intensities in fluorescence-optical imaging technique discriminates between disease activity and its response in antitnf treated psoriatic arthritis patients – an interims analysis of the xplore-study

Autor: Harald Burkhardt, G. Schmittat, Sarah Ohrndorf, A. C. Foldenauer, T. Rossmanith, M. Köhm, U. Henkemeier, J. Berger, Frank Behrens

Publikováno v: Spondyloarthritis – clinical aspects (other than treatment).

Background Psoriatic arthritis (PsA) is a chronic inflammatory disorder combining joint and musculoskeletal inflammation. AntiTNF-therapy is induced after failure of NSAID and DMARD treatment. Up to 30%–40% of the patients are primary not respondin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e31d88f5c738c755b31c0a1aee1edea2
https://doi.org/10.1136/annrheumdis-2018-eular.6764

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání